Promising therapeutic options in triple-negative breast cancer

Journal of B.U.ON.

Volumn 17, Issue 2, 2012, Pages 209-222

  Bilici, A ^a   Arslan, C ^b   Altundag, Kadri ^b  

^a SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Basal like; Breast cancer; Treatment; Triple negative

Indexed keywords

5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; BEVACIZUMAB; BRCA1 PROTEIN; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DASATINIB; DOCETAXEL; DOXORUBICIN; ENTINOSTAT; EPIRUBICIN; EVEROLIMUS; FLUOROURACIL; GEMCITABINE; INIPARIB; IXABEPILONE; MITOMYCIN C; OLAPARIB; PACLITAXEL; PANITUMUMAB; RETASPIMYCIN; SK 7041; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; CANCER CHEMOTHERAPY; DRUG EFFICACY; HUMAN; NONHUMAN; REVIEW; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84863617400     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005; 23: 7350-7360. (Pubitemid 46202348)
2. Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
3. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008; 26: 2568-2581.
4. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-5374. (Pubitemid 39100473)
5. Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-4434. (Pubitemid 47219710)
6. Kaplan HG, Malmgren JA, Atwood M. T1N0 Triple Negative Breast Cancer: Risk of Recurrence and Adjuvant Chemotherapy. Breast J 2009; 15: 454-460.
7. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 2007; 109: 1721-1728. (Pubitemid 46668532)
8. Carey LA, Perou CM, Livasy CA et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-2502. (Pubitemid 43854964)
9. Aksoy S, Dizdar O, Harputluoglu H, Altundag K. Demographic, clinical, and pathological characteristics of Turkish triple-negative breast cancer patients: single center experience. Ann Oncol 2007; 18: 1904-1906. (Pubitemid 350111578)
10. Van Calster B, Vanden Bempt I, Drijkoningen M et al. Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive. Breast Cancer Res Treat 2009; 113: 181-187.
11. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004; 4: 665-676. (Pubitemid 39215065)
12. Couch FJ. Genetic epidemiology of BRCA1. Cancer Biol Ther 2004; 3: 509-514. (Pubitemid 41351119)
13. Young SR, Pilarski RT, Donenberg T et al. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 2009; 9: 86.
14. Pal SK, Mortimer J. Triple-negative breast cancer: novel therapies and new directions. Maturitas 2009; 63: 269-274.
15. Atchley DP, Albarracin CT, Lopez A et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 2008; 26: 4282-4288.
16. Miyoshi Y, Murase K, Oh K. Basal-like subtype and BRCA1 dysfunction in breast cancers. Int J Clin Oncol 2008; 13: 395-400.
17. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene 2006; 25: 5846-5853. (Pubitemid 44453440)
18. Haffty BG, Yang Q, Reiss M et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006; 24: 5652-5657. (Pubitemid 46631305)
19. Morris GJ, Naidu S, Topham AK et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 2007; 110: 876-884. (Pubitemid 47257667)
20. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-1281.
21. Carey LA, Dees EC, Sawyer L et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329-2334. (Pubitemid 46698581)
22. Hayes DF, Thor AD, Dressler LG et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007; 357: 1496-1506. (Pubitemid 47572635)
23. Ellis P, Barrett-Lee P, Johnson L et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet 2009; 373: 1681-1692.
24. Rouzier R, Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678-5685. (Pubitemid 41170290)
25. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 2008; 14: 1291-1295. (Pubitemid 351413906)
26. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007; 7: 573-584. (Pubitemid 47106628)
27. Byrski T, Gronwald J, Huzarski T, Grzybowska E et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010; 28: 375-379.
28. Silver DP, Richardson AL, Eklund AC et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 2010; 28: 1145-1153.
29. Torrisi R, Balduzzi A, Ghisini R et al. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemother Pharmacol 2008; 62: 667-672.
30. Frasci G, Comella P, Rinaldo M et al. Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer. Ann Oncol 2009; 20: 1185-1192.
31. Yi S, Uhm J, Cho E et al. Clinical outcomes of metastatic breast cancer patients with triple-negative phenotype who received platinum-containing chemotherapy. Proc Am Soc Clin Oncol 2008; 26: 15S(abstr 1008).
32. Sirohi B, Arnedos M, Popat S et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 2008; 19: 1847-1852.
33. Uhm JE, Park YH, Yi SY et al. Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy. Int J Cancer 2009; 124: 1457-1462.
34. Isakoff SJ, Goss PE, Mayer EL et al. TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response. Proc Am Soc Clin Oncol 2011; 29: 15S (abstr 1025).
35. Di Leo A, Isola J, Piette F et al. A meta-analysis of phase III trials evaluating the predictive value of Her-2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. Breast Cancer Res Treat 2008; 107: 24.
36. Hugh J, Hanson J, Cheang MC et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009; 27: 1168-1176.
37. Bear HD, Anderson S, Brown A et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003; 21: 4165-4174. (Pubitemid 46606185)
38. Smith IC, Heys SD, Hutcheon AW et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002; 20: 1456-1466. (Pubitemid 34260523)
39. Sanchez-Munoz A, Garcia-Tapiador AM, Martinez-Ortega E et al. Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Clin Transl Oncol 2008; 10: 646-653.
40. Knoop AS, Knudsen H, Balslev E et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005; 23: 7483-7490. (Pubitemid 46291811)
41. Tanner M, Isola J, Wiklund T et al. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 2006; 24: 2428-2436. (Pubitemid 46630618)
42. Bond GL, Hu W, Bond EE et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119: 591-602. (Pubitemid 39535748)
43. Bidard FC, Matthieu MC, Chollet P et al. p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. Ann Oncol 2008; 19: 1261-1265. (Pubitemid 351916575)
44. Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 2010; 10: 194-204.
45. Pivot XB, Li RK, Thomas ES et al. Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer. Eur J Cance. 2009; 45: 2940-2946.
46. Baselga J, Zambetti M, Llombart-Cussac A et al. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J Clin Oncol 2009; 27: 526-534.
47. Thomas ES, Gomez HL, Li RK et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracyclines and taxane treatment. J Clin Oncol 2007; 25: 5210-5217. (Pubitemid 350232252)
48. Roche H, Li RK, Ro J. Ixabepilone plus capecitabine improves progression free survival in patients with metastatic breast cancer resistant to taxanes: a pooled analysis from two phase III trials. Cancer Res 2009; 69: S2 (abstr 2015).
49. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
50. Miles D, Chan A, Romieu G. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. Proc Am Soc Clin Oncol 2008; 26: 15S (abstr 1011).
51. Robert N, Dieras V, Glaspy J. Ribbon-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2009; 27: 15S (abstr 1005).
52. O'Shaughnessy J, Dieras V, Glaspy J et al. Comparison of Subgroup Analyses of PFS from Three Phase III Studies of Bevacizumab in Combination with Chemotherapy in Patients with HER2-Negative Metastatic Breast Cancer (MBC). Cancer Res 2009; 69: S1 (abstr 207)
53. Balduzzi A, Montagna E, Bagnardi V et al. Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features. Anticancer Drugs 2009; 20: 197-203.
54. Carey LA, Rugo HS, Marcom PK et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. Proc Am Soc Clin Oncol 2008; 26: 15S (abstr 1009).
55. O'Shaughnessy J, Weckstein DJ, Vukelja SJ et al. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Res Treat 2007; 106: S32 (abstr 308).
56. Baselga J, Stemmer S, Pego A et al. Cetuximab + Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results of the Randomized Phase II BALI-1 Trial. Cancer Res 2010; 70: 24S2 (abstr PD01-01).
57. Twelves C, Trigo JM, Jones R et al. Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study. Eur J Cancer 2008; 44: 419-426.
58. Dickler MN, Cobleigh MA, Miller KD et al. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2009; 115: 115-121.
59. Corkery B, Crown J, Clynes M, O'Donovan N. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol 2009; 20: 862-867.
60. Nabholtz J, Weber B, Mouret-Reynier M et al. Panitumumab in combination with FEC 100 (5-fluorouracil, epidoxorubicin, cyclophosphamide) followed by docetaxel (T) in patients with operable, triple-negative breast cancer (TNBC): Preliminary results of a multicenter neoadjuvant pilot phase II study. Proc Am Soc Clin Oncol 2011; 29: 15S (abstr e11574).
61. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet derived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-337. (Pubitemid 36109749)
62. Abrams TJ, Lee LB, Murray LJ et al. SU 11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2: 757-766.
63. Deeks ED, Keating GM. Sunitinib. Drugs 2006; 66: 2255-2266; discussion 67-68.
64. Burstein HJ, Elias AD, Rugo HS et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008; 26: 1810-1816.
65. Barrios C, Liu M, Lee S et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER 2 negative advanced breast disease (SUN 1107) Cancer Res 2009; 69: 24S1 (abstr 46).
66. Study of SU011248 versus chemotherapy for patients with previously treated triple receptor negative breast cancer. Available from: www.clinicaltrials.gov [Last accessed 26 August 2011].
67. Baselga J, Roche H, Costa F et al. SOLTI 0701: a multinational double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with capecitabine in patients with locally advanced or metastatic breast cancer Cancer Res 2009; 69: 24S1 (abstr 45).
68. Gradishar W, Kaklamani V, Prasad Sahoo T et al. A double-blind, randomized, placebo-controlled, phase 2b study evaluating the efficacy and safety of sorafenib in combination with paclitaxel as a first line therapy in patients with locally recurrent or metastatic breast cancer. Cancer Res 2009; 69: 24S1 (abstr 44).
69. Conlin AK, Seidman AD. Beyond cytotoxic chemotherapy for the first line treatment of HER 2-negative, hormone insensitive metastatic breast cancer current status and future opportunities. Clin Breast Cancer 2008; 8: 215-223. (Pubitemid 351962142)
70. Finn RS, Dering J, Ginther C et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007; 105: 319-326. (Pubitemid 47596452)
71. Verbeek B, Vroom T, Adriansen-Slot S et al. c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol 1996; 180: 383-388. (Pubitemid 27014075)
72. Phase II Study of Dasatinib (BMS-354825) for Advanced "Triple-Negative" Breast Cancer. Available from: www.clinicaltrials. gov [Last accessed 15 May 2009].
73. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134.
74. McCabe N, Turner NC, Lord CJ et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006; 66: 8109-8115. (Pubitemid 44299177)
75. Sahin I, Ararat E, Altundag K. BRCA-deficient and triple negative breast cancers: is olaparib effective in both subtypes? J BUON 2011; 16: 184-185.
76. O'Shaughnessy J, Osborne C, Pippen JE et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364: 205-214.
77. O'Shaughnessy J, Schwartzberg LS, Danso MA et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). Proc Am Soc Clin Oncol 2011; 29: 15S (abstr 1007).
78. Tutt A, Robson M, Garber JE et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376: 235-244.
79. Gelmon KA, Hirte HW, Robidoux A et al. Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. Proc Am Soc Clin Oncol 2010; 28: 15S (abstr 3002).
80. Dent R, Lindeman G, Clemons M et al. Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial. Proc Am Soc Clin Oncol 2010; 28: 15S (abstr 1018).
81. Isakoff SJ, Overmoyer B, Tung NM et al. A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. Proc Am Soc Clin Oncol 2010; 28: 15S (abstr 1019).
82. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009; 27: 2278-2287.
83. Saal LH, Holm K, Maurer M et al. PIK3CA mutations correlate with hormonoreceptors, node metastasis and ERBB2 and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005; 65: 2554-2559. (Pubitemid 40490050)
84. Ellard SL, Clemons M, Gelmon KA et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC clinical trials group IND.163. J Clin Oncol 2009; 27: 4536-4541.
85. Gonzalez-Angulo AM, Green MC, Murray JL et al. Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC). Proc Am Soc Clin Oncol 2011; 29: 15S (abstr 1016).
86. Gucalp A, Traina TA. Triple-negative breast cancer: role of the androgen receptor. Cancer J 2010; 16: 62-65.
87. Doane AS, Danso M, Lal P et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006; 25: 3994-4008. (Pubitemid 43990755)
88. Gonzalez-Angulo AM, Stemke-Hale K, Palla S et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 2009; 15: 2472-2478.
89. Park S, Koo J, Park HS et al. Expression of androgen receptors in primary breast cancer. Ann Oncol 2009; 21: 488-492.
90. Whitesell L, Mimmaugh E, De Costa B et al. Inhibition of HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 1994; 91: 8324-8328.
91. Modi S. Heat shock protein 90 inhibition: a novel strategy for the treatment of HER2-positive breast cancer. Cancer Res 2009; 24S1.
92. Caldas-Lopez E, Cerchietti L, Ahn J et al. Hsp90 inhibitor PUH71, a multimodal inhibitor of malignancy induces complete responses in triple negative breast cancer models. Proc Natl Acad Sci U S A 2009; 106: 8368-8373.
93. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-784. (Pubitemid 44348499)
94. Marks PA, Jiang X. Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle 2005; 4: 549-551. (Pubitemid 41359778)
95. Luu TH, Morgan RJ, Leong L et al. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res 2008; 14: 7138-7142.
96. Lee KW, Kim JH, Park JH et al. Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells. Anticancer Res 2006; 26: 3429-3438. (Pubitemid 44701519)
97. Nguyen NK, Korangath P, Sabnis G et al. A Combination of HDAC Inhibitor Entinostat (MS-275), All Trans Retinoic Acid (ATRA) and Chemotherapy Drug(s) Causes Regression of Established Xenografts of Triple Negative Breast Cancer. Cancer Res 2010; 70: 24S2 (abstr PD01-05).
98. Holoch PA, Griffith TS. TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol 2009; 625: 63-72.
99. Sadarangani A, Kato S, Espinoza N et al. TRAIL mediates apoptosis in cancerous but not normal primary cultured cells of the human reproductive tract. Apoptosis 2007; 12: 73-85. (Pubitemid 46009505)
100. Cretney E, Takeda K, Smyth MJ. Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway. Int J Biochem Cell Biol 2007; 39: 280-286. (Pubitemid 44855666)
101. Rainville C, Khan Y, Tisman G. Triple negative breast cancer patients presenting with low serum vitamin D levels: a case series. Cases J 2009; 2; 8390.
102. Verlinden L, Eelen G, Van Hellemont R et al. 1a,25-Dihydroxyvitamin D(3)-induced down regulation of the checkpoint proteins, Chk1 and claspin, is mediated by the pocket proteins p107 and p130. J Steroid Biochem Mol Biol 2007; 103: 411-415. (Pubitemid 46401349)
103. Harputluoglu H, Dizdar O, Karaahmet F, Altundag K. Vitamin D intake may be effective in the management of triple-negative breast cancer. J BUON 2011; 16: 569.